Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG Comments on FDA Plausible Mechanism Draft Guidance
-
Stakeholder Letter Opposing the Patent Eligibility Restoration Act (PERA)
-
Sign-on Letter Opposing the Patent Eligibility Restoraction Act of 2024
-
ACMG Response to RFI on Gene Therapies Access for Rare Diseases
-
Sign-on Letter Supporting the Saving Access to Laboratory Services Act
-
ACMG Comment to NCD on Germline Editing and Impact on People with Disabilities
-
Sign-on Letter Concerning Patent Legislation Negotiation Process
-
Group Letter to Biden Administration Regarding Patent Eligibility Reform
-
Group Sign-on Letter to Congress Expressing Concerns about Patent Eligibility Reform Stakeholder Discussions
-
ACMG Letter to CMS Requesting Reconsideration of Payment Determination for a PALB2 CPT Code 81307